We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ASX:IGAustralia 200 Cash (A$25) Analysis

Data as of 2026-06-09 - not real-time

$35.52

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

ASE Technology Holding (ASX) posted a robust Q1 2026 with revenue up 17.2% YoY and net income jumping 87%, driven by record assembly‑testing volumes. The stock trades at $35.52, comfortably above its 20‑day, 50‑day and 200‑day SMAs, indicating a bullish price trend, while the RSI of 52 suggests momentum is still neutral. Technical signals are mixed: volume is increasing and the trend is bullish, but the MACD histogram is negative and the signal line is bearish, hinting at possible short‑term pull‑back. Valuation metrics show a trailing PE of 53 versus an industry average of 33, and a PB of 7, which appear stretched, yet the forward PE of 22 and a modest 8.8% upside to the DCF‑derived fair value point to a slight undervaluation. The company carries a 67% debt‑to‑equity ratio and negative free cash flow, raising concerns about dividend sustainability despite a 1% yield and a 51% payout ratio.
Overall, ASX benefits from strong top‑line growth, strategic expansion in Taiwan, and a favorable analyst consensus (strong‑buy), but investors should weigh the high volatility (≈71% 30‑day), elevated beta, and cash flow pressures. The medium‑term outlook remains positive, while short‑term positioning may warrant caution pending further technical confirmation.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD divergence
  • High 30‑day volatility
  • Proximity to resistance at $41.10

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong Q1 revenue and earnings growth
  • Forward PE discount to industry
  • Strategic manufacturing partnership in Taiwan

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Secular demand for semiconductor packaging and testing
  • Solid ROE and cash position
  • Analyst consensus of strong‑buy with upside potential

Key Metrics & Analysis

Financial Health

Revenue Growth17.20%
Profit Margin7.04%
P/E Ratio53.0
ROE13.58%
ROA4.23%
Debt/Equity67.16
P/B Ratio7.0
Op. Cash Flow$158.7B
Free Cash Flow$-66127527936
Industry P/E33.3

Technical Analysis

TrendBullish
RSI51.8
Support$29.89
Resistance$41.10
MA 20$35.90
MA 50$31.09
MA 200$19.93
MACDBearish
VolumeIncreasing
Fear & Greed Index87.64

Valuation

Fair Value$1,277.24
Target Price$38.65
Upside/Downside8.81%
GradeUndervalued
TypeGrowth
Dividend Yield1.00%

Risk Assessment

Beta1.85
Volatility70.88%
Sector RiskHigh
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.